Your Source for BioScience Venture Capital Data
  • SEARCH THE OnBioVC DATABASE:

  • OnBioVC NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • Photobucket

  • FDA Registered Contract Manufacturer

New Haven Pharmaceuticals (New Haven, CT), a specialty pharmaceutical company focused on a slow release aspirin product, closed a $6.6M Series A. Participants include Connecticut Innovations and private investors.

Neurovance (Cambridge, MA), a clinical stage pharmaceutical company developing a norepinephrine, dopamine and serotonin triple uptake inhibitor to treat ADHD, closed a $7M Series A financing. Participants include Novartis Venture Fund and H&Q Life Sciences Investors.

Visterra (Cambridge, MA), a preclinical-stage biotechnology company focused on seasonal and pandemic influenza, closed a $13M Series A financing, bringing the total round to $26M. Participants include The Bill & Melinda Gates Foundation, Omega Funds, Polaris Venture Partners, Flagship Ventures and Lux Capital. Collective IP | The World’s Largest Technology Transfer Office Marketplace Providing Unrivaled [...]

Cibiem (New York, NY), a development-stage medical device company focused on sympathetic nervous system-mediated diseases, closed a $10M Series A financing. Participants include SV Life Sciences and Third Rock Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account [...]

Aclaris Therapeutics (Malvern, PA), a preclinical-stage pharmaceutical company focused on topical dermatological therapies, closed a $21M Series A financing. Participants include Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Neurovance (Cambridge, MA), a clinical-stage pharmaceutical company focused on treatments for CNS disorders such as adult attention deficit hyperactivity disorder, closed a $7M Series A financing. Participants include Novartis Venture Fund. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP [...]

Thesan Pharmaceuticals (San Clemente, CA), a preclinical biopharmaceutical company focused on dermatological disorders, closed a $16M Series A financing. Participants include Novo Ventures and Novartis Venture Funds. Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem Request Collective IP Account Access HERE

Principia Biopharma (San Francisco, CA), a biopharmaceutical company focused on immunology, autoimmune diseases and oncology, closed a $12.5M Series A financing, bringing the total round to $36.6M. Participants include New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SR One and Mission Bay Capital. Collective IP | The Most Comprehensive and Accurate View of Global Innovation [...]

GeneWeave Biosciences (San Jose, CA) a development-stage molecular diagnostic company focused on using bacterial DNA for the detection of pathogens, closed a $12M Series A financing. Participants include Decheng Capital, Claremont Creek Ventures and X/Seed Capital. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Strand Diagnostics (Indianapolis, IN) a commercial-stage molecular diagnostics company focused on DNA screening of breast and prostate biopsy samples and patient DNA for molecular cancer diagnosis verification, closed a $30M Series A financing. Participants include NantWorks. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Mnemosyne Pharmaceuticals (Providence, RI) a development-stage small molecule company focused on neuropsychiatric disorders such as schizophrenia and Alzheimer’s, closed a $5.4M Series financing Participants include Access BridgeGap Ventures and Slater Technology Fund. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

Vascular Magnetics (Philadelphia, PA) a development-stage medical device focused on magnetically targeted drug delivery for the treatment of peripheral artery disease, closed a $7M Series A financing. Participants include Devon Park Bioventures. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

4s3 Bioscience (Medford, MA) a preclinical-stage biotherapeutics company focused on developing genetics disease therapies for orphan neuromuscular disorders, closed a $20M Series A financing. Participants include KLP Enterprises. Note: Closing out 1Q deals. Thanx for your patience as we play catch-up.

« Previous Entries  Next Page »

to top of page...